Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery Of Novel Next-Generation Oxytocin Analogues At The American Chemistry Society Spring 2024 Meeting
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery Of Novel Next-Generation Oxytocin Analogues At The American Chemistry Society Spring 2024 Meeting
Tonix Pharmicals宣布在美国化学学会2024年春季会议上发布海报，描述新型下一代催产素类似物的发现
Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder
研究人员发起的四项针对儿科肥胖、暴饮暴食、自闭症骨骼健康和社交焦虑症的 TNX-1900（鼻内增强催产素）的二期研究正在进行中
TNX-2900 (intranasal potentiated oxytocin) is being developed under an IND as a treatment for Prader-Willi Syndrome, an Orphan Disease characterized by excessive eating
TNX-2900（鼻内强化催产素）是根据临床试验研究开发的，用于治疗普拉德-威利综合症，这是一种以过度进食为特征的孤儿病
TNX-1900 and TNX-2900 may serve as novel neuroendocrine treatments for certain pain, eating and endocrine disorders
TNX-1900 和 TNX-2900 可用作某些疼痛、进食和内分泌失调的新型神经内分泌治疗方法
CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at...
新泽西州查塔姆，2024年3月21日（GLOBE NEWSWIRE）...
登录免费看全文
登录/注册
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。